Penumbra, Inc. (NYSE:PEN) Shares Acquired by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. boosted its holdings in Penumbra, Inc. (NYSE:PEN - Free Report) by 3.5% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 60,485 shares of the company's stock after purchasing an additional 2,033 shares during the period. Envestnet Asset Management Inc. owned about 0.16% of Penumbra worth $14,364,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Penumbra in the 4th quarter valued at about $573,000. E. Ohman J or Asset Management AB increased its holdings in Penumbra by 10.4% in the fourth quarter. E. Ohman J or Asset Management AB now owns 21,312 shares of the company's stock valued at $5,061,000 after buying an additional 2,000 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in Penumbra by 1.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 271,574 shares of the company's stock valued at $64,493,000 after buying an additional 3,807 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Penumbra by 1.7% during the 3rd quarter. Geode Capital Management LLC now owns 655,572 shares of the company's stock worth $127,417,000 after buying an additional 11,257 shares during the last quarter. Finally, Washington Capital Management Inc. acquired a new position in shares of Penumbra in the 4th quarter worth approximately $226,000. Institutional investors and hedge funds own 88.88% of the company's stock.

Wall Street Analysts Forecast Growth

PEN has been the topic of several research reports. Royal Bank of Canada reissued an "outperform" rating and set a $315.00 price target on shares of Penumbra in a research report on Tuesday, April 15th. StockNews.com cut shares of Penumbra from a "buy" rating to a "hold" rating in a report on Friday, February 28th. Morgan Stanley lifted their price target on shares of Penumbra from $240.00 to $260.00 and gave the company an "equal weight" rating in a report on Wednesday, February 19th. Needham & Company LLC reiterated a "hold" rating on shares of Penumbra in a research note on Wednesday, February 19th. Finally, Wells Fargo & Company lifted their target price on Penumbra from $275.00 to $305.00 and gave the company an "overweight" rating in a research note on Wednesday, February 19th. Four equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Penumbra presently has an average rating of "Moderate Buy" and an average price target of $293.93.

Insider Activity at Penumbra

In other news, CEO Adam Elsesser sold 16,560 shares of the firm's stock in a transaction dated Wednesday, April 16th. The shares were sold at an average price of $274.35, for a total transaction of $4,543,236.00. Following the completion of the transaction, the chief executive officer now owns 63,911 shares in the company, valued at approximately $17,533,982.85. This trade represents a 20.58 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Johanna Roberts sold 600 shares of Penumbra stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $287.43, for a total transaction of $172,458.00. Following the completion of the transaction, the executive vice president now directly owns 66,539 shares in the company, valued at $19,125,304.77. This represents a 0.89 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 127,846 shares of company stock worth $35,779,187 over the last quarter. 5.00% of the stock is currently owned by company insiders.

Penumbra Stock Performance

PEN stock traded up $5.25 during trading on Tuesday, reaching $275.89. 728,375 shares of the company's stock were exchanged, compared to its average volume of 415,943. The firm has a market cap of $10.67 billion, a PE ratio of 811.44, a P/E/G ratio of 2.83 and a beta of 0.56. The company has a quick ratio of 3.25, a current ratio of 6.01 and a debt-to-equity ratio of 0.02. Penumbra, Inc. has a 1-year low of $148.00 and a 1-year high of $310.00. The company's fifty day moving average price is $275.59 and its 200-day moving average price is $252.75.

Penumbra (NYSE:PEN - Get Free Report) last announced its earnings results on Tuesday, February 18th. The company reported $0.97 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.88 by $0.09. Penumbra had a net margin of 1.17% and a return on equity of 9.74%. The firm had revenue of $315.52 million during the quarter, compared to analyst estimates of $311.63 million. On average, research analysts expect that Penumbra, Inc. will post 3.67 EPS for the current fiscal year.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.